China Regenerative Medicine International Ltd
HKEX:8158
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| HK |
C
|
China Regenerative Medicine International Ltd
HKEX:8158
|
117.1m HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -36 930 000% |
| 30th Percentile | -5.1% |
| Median | 2.5% |
| 70th Percentile | 9.4% |
| Max | 8 238.3% |
Other Profitability Ratios
China Regenerative Medicine International Ltd
Glance View
China Regenerative Medicine International Ltd. is an investment holding company, which engages in in research and development of medical and healthcare products. Along with subsidiaries, the Company operates its business through four segments. The Medical Equipment segment is involved in trading of medical equipments. The Tissue Engineering segment is involved in production and sale of tissue engineering products. The Cosmetic and Others segment is involved in production and sales of cosmetic, healthcare and other products. The Stem Cell segment is involved in research of cellular and stem cell therapy, sales and distribution of stem cell medical equipment, as well as the provision of other services.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for China Regenerative Medicine International Ltd is 2.8%, which is above its 3-year median of -26.9%.
Over the last 3 years, China Regenerative Medicine International Ltd’s Operating Margin has increased from -1.7% to 2.8%. During this period, it reached a low of -153.7% on Dec 31, 2023 and a high of 20.5% on Dec 31, 2024.
